RDHLRedHill Biopharma Ltd.
The schedule
- Sun15Nov
Deadline to address Nasdaq's minimum bid price requirement, likely necessitating a reverse stock split if organic compliance fails.
- Mon23Nov
Expected updates on the clinical pipeline and regulatory interactions, which serve as primary organic growth levers.
- Fri12Feb
- Thu25Mar
Year-end financial results coupled with a potential strategic review of commercial assets and operational viability.
Past
- Fri14Aug
Actual outcome: Bear
RedHill Biopharma reported Q2 earnings that met expectations, with EPS coming in exactly at the estimated -$1.00. Despite the in-line results, the lack of positive forward catalysts or upside surprises failed to attract buyers, leading the stock to drift lower and settle well below the bear floor.
- Fri14Aug
Actual outcome: Bear
RedHill Biopharma reported Q3 EPS of -$1.00, exactly meeting consensus estimates. With no major surprises in the quarterly print regarding revenue stability or cash runway projections, the stock experienced a muted reaction and traded relatively flat.
Quarterly earnings print evaluating revenue stability and updated cash runway projections.
- Wed22Jul
Actual outcome: Bear · $0.67 at outcome
Although RedHill provided an update on ongoing partnership discussions regarding Opaganib for the Ebola outbreak, the company failed to announce a definitive financing or partnering transaction. Without a concrete resolution to address its depleted cash reserves and ongoing operational burn, the stock drifted lower and eventually broke below the bear floor.
Market anticipation of a critical funding event given the depleted cash reserves and ongoing operational burn.
- Fri15May
Actual outcome: Bear · $0.83 at outcome
RedHill Biopharma reported Q1 2026 EPS of -$1.00, which met analyst estimates. However, the stock fell 19.4% following the release as the company's cash runway update and sales trends failed to reassure investors regarding future funding needs. Consequently, the market priced in higher dilution risk, driving the shares lower.
Q1 2026 results and a detailed cash runway update from RedHill Biopharma at a share price of $0.83. A credible path toward further revenue growth and cost control, along with clarity on funding needs, could support a move toward $1.05, while weaker sales trends or a shorter-than-expected runway could push the stock down toward $1.05 as the market prices in higher dilution risk.
